Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | NAAA | Q02083 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360165 | 0.91 | TSHR (0.56) | TSHRHTTHPGDNAAAHDAC3 | |
| SCHEMBL9489936 | 0.89 | HDAC3 (0.67) | TSHRHTTHPGDNAAAHDAC3 | |
| SCHEMBL19210845 | 0.84 | TSHR (1.00) | TSHRHTTHPGDNAAAL3MBTL1 | |
| SCHEMBL17938589 | 0.81 | TSHR (0.64) | TSHRHTTHPGDNAAAL3MBTL1 | |
| SCHEMBL28961104 | 0.78 | ALOX15 (0.47) | HPGDHDAC3HDAC1ALOX15ALDH1A1 | |
| SCHEMBL486382 | 0.78 | TSHR (0.80) | TSHRHTTHPGDNAAAHDAC3 | |
| SCHEMBL164069 | 0.78 | TSHR (0.80) | TSHRHTTHPGDNAAAL3MBTL1 | |
| SCHEMBL3148607 | 0.78 | NAAA (0.88) | TSHRHTTHPGDNAAAL3MBTL1 | |
| SCHEMBL6273378 | 0.78 | HTT (0.86) | TSHRHTTHPGDNAAAL3MBTL1 | |
| SCHEMBL9260536 | 0.77 | HTT (0.86) | TSHRHTTHPGDNAAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | TSHR 184/4885HTT 4255/4885HPGD 2359/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | TSHR 184/4885HTT 4255/4885HPGD 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.